GE

255.78

+1.67%↑

RTX

139.19

+0.19%↑

CAT

353.42

+1.42%↑

BA

210.99

+0.98%↑

HON

228.84

+1.06%↑

GE

255.78

+1.67%↑

RTX

139.19

+0.19%↑

CAT

353.42

+1.42%↑

BA

210.99

+0.98%↑

HON

228.84

+1.06%↑

GE

255.78

+1.67%↑

RTX

139.19

+0.19%↑

CAT

353.42

+1.42%↑

BA

210.99

+0.98%↑

HON

228.84

+1.06%↑

GE

255.78

+1.67%↑

RTX

139.19

+0.19%↑

CAT

353.42

+1.42%↑

BA

210.99

+0.98%↑

HON

228.84

+1.06%↑

GE

255.78

+1.67%↑

RTX

139.19

+0.19%↑

CAT

353.42

+1.42%↑

BA

210.99

+0.98%↑

HON

228.84

+1.06%↑

Search

India Globalization Capital Inc

Închisă

0.3

Rezumat

Modificarea prețului

24h

Curent

Minim

0.3

Maxim

0.31

Indicatori cheie

By Trading Economics

Venit

-112K

-1.8M

Vânzări

-155K

257K

Marjă de profit

-711.673

Angajați

67

EBITDA

-106K

-1.7M

Dividende

By Dow Jones

Următoarele câștiguri

20 iun. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

25M

Deschiderea anterioară

0.3

Închiderea anterioară

0.3

India Globalization Capital Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 sept. 2024, 04:00 UTC

Top știri

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

Comparație

Modificare preț

India Globalization Capital Inc Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre India Globalization Capital Inc

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.